Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration–Primary End Point
Author:
Publisher
Elsevier BV
Subject
Ophthalmology
Reference11 articles.
1. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006
2. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006
3. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;Martin;N Engl J Med,2011
4. Novel method for analyzing Snellen visual acuity measurements;Gregori;Retina,2010
5. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients;Brown;Am J Ophthalmol,2007
Cited by 79 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab;Ophthalmology and Therapy;2024-08-30
2. Simultaneous Intravitreal Steroid and Anti-VEGF Therapy for Monotherapy-Resistant Chronic Wet Age-Related Macular Degeneration;Ophthalmic Surgery, Lasers and Imaging Retina;2024-08
3. Real-World Weekly Efficacy Analysis of Faricimab in Patients with Age-Related Macular Degeneration;Bioengineering;2024-05-10
4. Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes;Medicine;2024-04-19
5. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial;The Lancet;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3